News

Find out more about us and our portfolio companies

All years

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2026/03/20
Repronovo Appoints Mark Altmeyer as Chairman of the Board

Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 – ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors.
2026/03/18
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy

2026/03/20
Repronovo Appoints Mark Altmeyer as Chairman of the Board
2026/03/18
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
2026/03/18
Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
2026/03/02
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
2026/02/26
Celebrate women in science with Optimum
2026/02/23
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
2026/01/29
Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery
2026/01/29
UNISERS Ships First Fully-Automated Fab Tool and Strengthens Leadership to Scale In-Fab Deployment
2026/01/16
SEEQC and Allegro Merger Corp. Enter Into Merger Agreement
2026/01/16
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
2026/01/13
Altoida and Mindspan Announce Research Collaboration to Use AI/AR-Powered Digital Cognitive Assessment to Personalize Cognitive Care
2026/01/12
Iktos named Top BioTech and Life Sciences Companies of 2025
2026/01/12
Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology
2026/01/09
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration
2026/01/09
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
2026/01/09
M Ventures: Pharma CVC and biotech innovation in 2026
2026/01/08
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

Find out more about us and our portfolio companies

Repronovo Appoints Mark Altmeyer as Chairman of the Board

Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy

Repronovo Appoints Mark Altmeyer as Chairman of the Board

Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)

Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

Celebrate women in science with Optimum

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery

UNISERS Ships First Fully-Automated Fab Tool and Strengthens Leadership to Scale In-Fab Deployment

SEEQC and Allegro Merger Corp. Enter Into Merger Agreement

Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication

Altoida and Mindspan Announce Research Collaboration to Use AI/AR-Powered Digital Cognitive Assessment to Personalize Cognitive Care

Iktos named Top BioTech and Life Sciences Companies of 2025

Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology

Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

M Ventures: Pharma CVC and biotech innovation in 2026

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s